 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...183184185186187188189190191192193...235236» |
- |||| dilpacimab (ABT-165) / AbbVie
Enrollment open, Trial initiation date, Metastases: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (clinicaltrials.gov) - Feb 23, 2018
P2, N=100, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: TCOG T5217: SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 23, 2018
P2, N=130, Not yet recruiting, Sponsor: National Health Research Institutes, Taiwan
- | Trial primary completion date: Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma (clinicaltrials.gov) - Feb 22, 2018
P2, N=2, Terminated, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018 Trial primary completion date: Mar 2016 --> Nov 2012
- |||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Metastases: INVICTAN (clinicaltrials.gov) - Feb 22, 2018
P3, N=123, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Mar 2016 --> Nov 2012 Trial primary completion date: Jan 2019 --> Sep 2018 | Trial completion date: Jan 2019 --> Sep 2018
- ||| spartalizumab (PDR001) / Novartis
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Feb 20, 2018
P1, N=92, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2019 --> Sep 2018 | Trial completion date: Jan 2019 --> Sep 2018 Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2021 --> Jun 2019 | Trial completion date: Jan 2021 --> Jun 2019
- | Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
New P1/2 trial, Combination therapy, Metastases: Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 20, 2018
P1/2, N=43, Not yet recruiting, Sponsor: Aadi, LLC
- |||| Vectibix (panitumumab) / Amgen
Enrollment open, Trial initiation date: OPALO: FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (clinicaltrials.gov) - Feb 19, 2018
P2, N=80, Recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2021 --> Jun 2019 | Trial completion date: Jan 2021 --> Jun 2019 Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Oct 2017
- Sotyktu (deucravacitinib) / BMS
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients (clinicaltrials.gov) - Feb 19, 2018
P1, N=12, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Oct 2017 Not yet recruiting --> Recruiting | Trial completion date: Apr 2018 --> Apr 2018 | Initiation date: Jan 2018 --> Jan 2018 | Trial primary completion date: Apr 2018 --> Apr 2018
- | methotrexate / Generic mfg.
Clinical, Journal: Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. (Pubmed Central) - Feb 18, 2018
Nephrotoxicity is a possible complication of therapy with high-dose methotrexate with most instances comprising grade 1-2 toxicity. Male gender, low albumin, and administration of interacting drugs or furosemide during high-dose methotrexate clearance may predispose patients to nephrotoxicity.
- ||| Alymsys (bevacizumab-maly) - Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi / Iko, Stada
Trial completion, Trial completion date, Trial initiation date: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN (clinicaltrials.gov) - Feb 15, 2018
P1, N=142, Completed, Sponsor: mAbxience S.A
Male gender, low albumin, and administration of interacting drugs or furosemide during high-dose methotrexate clearance may predispose patients to nephrotoxicity. Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2017 | Initiation date: Oct 2014 --> Oct 2014
- Davanat (galactomannan) / Galectin Therap
Enrollment change, Trial withdrawal, Combination therapy, Metastases: A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer (clinicaltrials.gov) - Feb 14, 2018
P2, N=0, Withdrawn, Sponsor: Galectin Therapeutics Inc.
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2017 | Initiation date: Oct 2014 --> Oct 2014 N=10 --> 0 | Terminated --> Withdrawn
- Xpovio (selinexor) / Karyopharm
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: SENTINEL: Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 14, 2018
P1, N=10, Completed, Sponsor: GSO Global Clinical Research BV
N=10 --> 0 | Terminated --> Withdrawn Active, not recruiting --> Completed | N=27 --> 10 | Trial completion date: Apr 2018 --> Mar 2017 | Trial primary completion date: Jun 2017 --> Mar 2017
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Feb 14, 2018
P3, N=1266, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=27 --> 10 | Trial completion date: Apr 2018 --> Mar 2017 | Trial primary completion date: Jun 2017 --> Mar 2017 Trial primary completion date: Jul 2019 --> Mar 2020 | Trial completion date: Oct 2020 --> Oct 2021
- | Erbitux (cetuximab) / Eli Lilly, cetuximab biosimilar / CinnaGen
Trial completion date, Trial primary completion date, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Feb 14, 2018
P3, N=234, Recruiting, Sponsor: Cinnagen
Trial primary completion date: Jul 2019 --> Mar 2020 | Trial completion date: Oct 2020 --> Oct 2021 Trial primary completion date: Feb 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Feb 2020
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Feb 12, 2018
P1, N=32, Active, not recruiting, Sponsor: Oncolytics Biotech
Trial primary completion date: Feb 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Feb 2020 Trial primary completion date: Feb 2018 --> Oct 2018 | Trial completion date: Apr 2018 --> Dec 2018
- | Enrollment closed, Metastases: LAPC-1: Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer. (clinicaltrials.gov) - Feb 12, 2018
P=N/A, N=53, Active, not recruiting, Sponsor: Foundation for Liver Research
Trial primary completion date: Feb 2018 --> Oct 2018 | Trial completion date: Apr 2018 --> Dec 2018 Recruiting --> Active, not recruiting
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Feb 12, 2018
P1b, N=9, Active, not recruiting, Sponsor: Oncolytics Biotech
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Oct 2018 | Trial completion date: Mar 2018 --> Dec 2018
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 9, 2018
P2, N=120, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jan 2018 --> Oct 2018 | Trial completion date: Mar 2018 --> Dec 2018 Trial primary completion date: Jul 2017 --> Mar 2018
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 9, 2018
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jul 2017 --> Mar 2018 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
New P2/3 trial: INCAGI004: Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer. (clinicaltrials.gov) - Feb 9, 2018
P2/3, N=63, Completed, Sponsor: Instituto Nacional de Cancer, Brazil
- | Enrollment closed, Enrollment change: Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study (clinicaltrials.gov) - Feb 8, 2018
P=N/A, N=1, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | N=28 --> 1
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Trial initiation date: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Feb 8, 2018
P2, N=140, Not yet recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting | N=28 --> 1 Initiation date: Nov 2017 --> May 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, Metastases: Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer (clinicaltrials.gov) - Feb 8, 2018
P3, N=560, Not yet recruiting, Sponsor: Kyungpook National University
- | Trial completion date, Trial primary completion date, Metastases: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (clinicaltrials.gov) - Feb 7, 2018
P4, N=36, Recruiting, Sponsor: University of Chicago
Initiation date: Nov 2017 --> May 2018 Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Jan 2018 --> Jan 2019
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (clinicaltrials.gov) - Feb 6, 2018
P2, N=35, Recruiting, Sponsor: John Hays
Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Jan 2018 --> Jan 2019 Trial primary completion date: Dec 2017 --> Dec 2018
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Feb 6, 2018
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019
- || andecaliximab (GS-5745) / Gilead
Enrollment closed, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 6, 2018
P1, N=236, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019 Recruiting --> Active, not recruiting
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Mismatch repair, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Feb 6, 2018
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma (clinicaltrials.gov) - Feb 5, 2018
P2, N=35, Recruiting, Sponsor: Yuhong Li
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Sep 2018
- | oxaliplatin / Generic mfg.
Trial primary completion date: Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer (clinicaltrials.gov) - Feb 5, 2018
P3, N=188, Recruiting, Sponsor: Yuhong Li
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Aug 2017 --> Aug 2018
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial primary completion date, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Feb 5, 2018
P1, N=18, Recruiting, Sponsor: National Cancer Centre, Singapore
Trial primary completion date: Aug 2017 --> Aug 2018 Trial primary completion date: Dec 2017 --> Jun 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Feb 5, 2018
P2, N=60, Recruiting, Sponsor: howard safran
Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Jan 2018 --> Jan 2020 | Trial completion date: Jul 2018 --> Jul 2020
- | Tecentriq (atezolizumab) / Roche
New P2 trial, Combination therapy: DANTE: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (clinicaltrials.gov) - Feb 5, 2018
P2, N=295, Not yet recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer (clinicaltrials.gov) - Feb 1, 2018
P2, N=180, Active, not recruiting, Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Trial primary completion date: Jan 2018 --> Jan 2020 | Trial completion date: Jul 2018 --> Jul 2020 Trial primary completion date: Dec 2017 --> May 2018
- | Avastin (bevacizumab) / Roche
Biomarker, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jan 31, 2018
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> May 2018 Trial primary completion date: Dec 2017 --> Jun 2018
- |||||||||| Opdivo (nivolumab) / BMS
New P2/3 trial: CheckMate 9X8: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (clinicaltrials.gov) - Jan 30, 2018
P2/3, N=180, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Erbitux (cetuximab) / Eli Lilly, cetuximab biosimilar / CinnaGen
Enrollment open, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Jan 30, 2018
P3, N=234, Recruiting, Sponsor: Cinnagen
Trial primary completion date: Dec 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- | New P3 trial: Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy (clinicaltrials.gov) - Jan 30, 2018
P3, N=764, Not yet recruiting, Sponsor: LI XIN-XIANG
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 29, 2018
P2, N=60, Not yet recruiting, Sponsor: Liqiang Zhong
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: Phase I Study of the Combination of Apatinib and POF (clinicaltrials.gov) - Jan 26, 2018
P1, N=18, Recruiting, Sponsor: Fujian Cancer Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 25, 2018
P1, N=26, Completed, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=34 --> 26 | Trial primary completion date: Nov 2018 --> Jan 2018
- ||||| Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: INTEGA: Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (clinicaltrials.gov) - Jan 24, 2018
P2, N=97, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- | Removab (catumaxomab) / NeoPharm, Trion Pharma
Trial completion: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (clinicaltrials.gov) - Jan 23, 2018
P2, N=42, Completed, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Completed | N=34 --> 26 | Trial primary completion date: Nov 2018 --> Jan 2018 Active, not recruiting --> Completed
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial initiation date, Trial primary completion date, Surgery, Metastases: Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 23, 2018
P1, N=8, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed Initiation date: Mar 2017 --> Oct 2016 | Trial primary completion date: Jan 2018 --> Dec 2018
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jan 23, 2018
P2, N=46, Not yet recruiting, Sponsor: National Health Research Institutes, Taiwan
- | Trial primary completion date, Surgery, Metastases: Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer (clinicaltrials.gov) - Jan 19, 2018
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Initiation date: Mar 2017 --> Oct 2016 | Trial primary completion date: Jan 2018 --> Dec 2018 Trial primary completion date: Jan 2018 --> Jan 2019
- | Trial primary completion date, Surgery: GCC 1324: Borderline Pancreas Study: FOLFIRINOX +SBRT (clinicaltrials.gov) - Jan 19, 2018
P1, N=20, Recruiting, Sponsor: University of Maryland
Trial primary completion date: Jan 2018 --> Jan 2019 Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial primary completion date: ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis (clinicaltrials.gov) - Jan 19, 2018
P2, N=220, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Mar 2018 --> Mar 2019
- | Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer (clinicaltrials.gov) - Jan 19, 2018
P2, N=30, Active, not recruiting, Sponsor: Bruckner Oncology
Trial primary completion date: Mar 2018 --> Mar 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018
- | leucovorin calcium / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study (clinicaltrials.gov) - Jan 19, 2018
P1, N=7, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018 Active, not recruiting --> Completed | N=12 --> 7 | Trial primary completion date: Dec 2018 --> Jan 2018